Lipoprotein lipase (LPL)1 catalyzes the hydrolysis of triglycerides in plasma chylomicrons and very low density lipoproteins (VLDL) (1-4). In humans, deficiency of either LPL or apolipoprotein (apo) CII, an essential cofactor for LPL's lipolytic activity, results in severe elevation in plasma chylomicrons and large VLDL (5). In addition to its lipolytic actions, LPL is also a ligand for receptors belonging to the family of low density lipoprotein (LDL) receptors, including LDL receptorrelated protein (LRP)/␣ 2 -macroglobulin (␣ 2 M) receptor, GP330/ LRP-2, and VLDL receptors (6 -13). LPL can influence lipoprotein catabolism by simultaneously binding to both lipoproteins and these cell surface receptors (6 -13). LPL promotes VLDL catabolism in LDL receptor-lacking mutant fibroblasts, and ligands specific for LRP inhibit LPL-stimulated VLDL degradation (9). LPL promotes lipoprotein binding to purified LRP (9) and GP330/LRP-2 (11) in solid-phase assays. Argraves et al. (12) demonstrated that transfection of PEA13 cells with VLDL receptors enhances their ability to internalize and degrade 125 I-LPL. Takahashi et al. (13) showed that in chinese hamster ovary cells co-transfected with the VLDL receptor and LPL, binding and degradation of 125 I-VLDL is much greater than in cells transfected with VLDL receptor alone. These studies demonstrate that LPL-dependent VLDL catabolism is mediated by LRP (6 -10), GP330/LRP-2 (10, 11), and VLDL receptors (12, 13). LPL also binds to cell surface heparan sulfate proteoglycans (3, 14 -16). LPL binding to either heparan sulfate proteoglycans or receptors can be separated from its lipolytic activity as indicated by studies with LPLC, the carboxyl-terminal, noncatalytic domain of LPL (8,17,18).